Last updated: May 21, 2026
Ultomiris (ravulizumab-cwvz, Ultomiris) is a terminal complement C5 inhibitor for PNH and atypical hemolytic uremia syndrome (aHUS). The last major competitive and regulatory inflection is the patent-and-exclusivity landscape around C5 complement inhibitors and the ongoing expansion of ravulizumab into additional patient segments. A market forecast depends on (i) dosing schedule durability, (ii) payer adoption versus Soliris-based strategies, and (iii) any entry of biosimilars or inter-IL comp comparators in the complement C5 inhibitor class.
What clinical trials are ongoing or most recently updated for Ultomiris (ravulizumab-cwvz)?
Featured snippet answer: The most decision-relevant clinical updates for Ultomiris are typically in (1) PNH long-term extension durability, (2) aHUS durability and sequencing, (3) pediatric and weight-tier dosing expansions, and (4) comparative effectiveness in clinical practice settings. Without a specific trial-by-trial dataset and dates, this section cannot be completed with hard, source-verified milestone claims.
Which indications drive Ultomiris trial readouts (PNH and aHUS)?
For high-intent market and IP planning, the trial activity to monitor is concentrated around:
- PNH: durability of LDH normalization and transfusion independence over long-term follow-up
- aHUS: renal outcomes, thrombotic microangiopathy (TMA) control, and complement pathway suppression durability
- Pediatric enrollment and dosing: pharmacokinetic (PK) and safety confirmation across weight bands
How do new trials change payer adoption for complement C5 inhibitors?
Clinical trial endpoints that materially affect market uptake:
- Sustained hemolysis control without rescue therapy
- Reduced relapse rates and stable dosing adherence
- Renal function stabilization metrics and time-to-TMA response
- Safety profile consistency (infections, meningococcal risk management)
How big is the Ultomiris market and what share does it capture versus Soliris (eculizumab)?
Featured snippet answer: This section cannot be completed with complete accuracy because no sales, prescribing, or reimbursement data were provided, and the required hard data inputs for 1) current U.S. and ex-U.S. revenue and 2) share against Soliris and other complement inhibitors are not available in this request.
What market segments matter most for Ultomiris revenue?
- U.S. and EU hospital and specialty center prescribing for PNH
- Nephrology-led aHUS management and center-of-excellence referral patterns
- Long-term maintenance therapy switching from eculizumab to ravulizumab where administratively favorable
What pricing and administration factors influence share gains over eculizumab?
- Dosing interval convenience (maintenance schedule length drives infusion/clinic efficiency)
- Switching friction (patient continuity, meningococcal vaccination protocol management)
- Payer formulary dynamics (step edits, prior authorization, specialty pharmacy vs in-hospital pathways)
When does Ultomiris lose exclusivity, and what are the key patent-expiration dates that matter for revenue?
Featured snippet answer: This section cannot be completed because the request does not include the Orange Book status, patent list, or jurisdictional expiration dates tied to Ultomiris. Without those, there is no defensible, litigation-ready exclusivity timeline.
Which exclusivity layers typically protect C5 inhibitor biologics?
- U.S. biologics exclusivity (BLA-related exclusivity periods)
- Composition-of-matter and formulation or method-of-use patents
- Additional protection from pediatric exclusivity, if applicable
- Any settlement-driven “no-approval” covenants (where present)
How to model revenue risk from exclusivity loss
Revenue projections in this class usually hinge on:
- Timing of first biosimilar entry vs “switching” behavior
- Uptake of biosimilars by payer and provider
- Contracting and rebate pressure after entry
What Paragraph IV or biosimilar risks exist for Ultomiris?
Featured snippet answer: This section cannot be completed with accuracy because it requires a current listing of biosimilar applications, FDA actions, and any related litigation records.
What to watch for in biosimilar risk modeling
- FDA acceptance and first filing for C5 complement inhibitors in the same therapeutic space
- Whether applicants target the same labeled indications and dosing schedule
- Any competitive entrants with pegylated/extended dosing or alternative C5-binding constructs
- Switching and contracting strategies post-approval
What formulations and delivery systems are protected for Ultomiris?
Featured snippet answer: This section cannot be completed because it requires patent and regulatory-formulation detail tied to Ultomiris manufacturing and composition.
What formulation categories usually impact IP and launch barriers?
- Concentration, stabilizers, buffer systems
- Lyophilized vs liquid presentation (if applicable)
- Container-closure system and shelf-life-related patents
- Manufacturing process patents (cell line, purification, filtration)
How manufacturing IP affects launch timing
For biologics, launch delay often comes from:
- Process reproducibility and comparability requirements
- Analytical similarity datasets and process validation time
- Scale-up capacity at contract manufacturers
What patent estate strength protects Ultomiris, and how strong is it versus competing C5 inhibitors?
Featured snippet answer: This section cannot be completed with the required hard data because no patent list, jurisdiction set, or expiration matrix was provided for Ultomiris or its key competitors.
Comparison framework for ravulizumab vs eculizumab and other complement inhibitors
An IP-strength comparison should be built from:
- Number of active patents by category (composition, method-of-use, formulation, manufacturing)
- Remaining life by jurisdiction (U.S., EU5, UK, Japan, etc.)
- Injunction risk from active litigation or enforceable patents
- Settlement or licensing constraints that narrow generic/biosimilar pathways
What FDA regulatory status does Ultomiris have, and what label expansions matter for projection?
Featured snippet answer: This section cannot be completed because the request does not include FDA label version, approval dates, or post-marketing labeling updates.
What regulatory milestones typically drive market growth
- Expanded pediatric or adult subgroup labeling
- Additional geographic approvals (EU member states and other territories)
- Safety updates affecting risk management programs
How label expansion affects revenue forecasts
A label expansion can shift:
- Eligibility criteria and patient access
- Network-of-care referral patterns
- Payer willingness to cover within newly eligible categories
What competitive landscape changes affect Ultomiris projections (switching, new entrants, contracting)?
Featured snippet answer: This section cannot be completed with accuracy because it requires competitor-by-competitor factual updates (market access, reimbursement, uptake, and competitor pipeline status).
Switching dynamics between eculizumab (Soliris) and ravulizumab (Ultomiris)
Modeling drivers:
- Clinic infusion scheduling benefits
- Switch clinical outcomes and prior authorization cadence
- Payer mandates after contract renegotiations
Alternative terminal complement and proximal complement strategies
Market share risk could come from:
- Complement inhibitors with differentiated dosing or administration
- Non-C5 mechanisms that fit payer preference or clinical guidelines
Key Takeaways
- Ultomiris is a long-duration complement C5 inhibitor franchise supported by PNH and aHUS use.
- Revenue projection hinges on exclusivity durability, biosimilar/biologic competition timing, and payer switching behavior.
- This request does not include the patent-exclusivity record, FDA label milestones, clinical trial registry update dates, or market sales inputs needed to produce a defensible, numbers-driven projection and patent risk assessment.
FAQs
- What endpoints in PNH and aHUS trials most influence Ultomiris reimbursement decisions?
- How should investors model ravulizumab biosimilar entry risk in the U.S. and EU?
- Which Ultomiris patient segments typically have the highest switching rates from eculizumab?
- What evidence matters most for payers when updating prior authorization criteria for C5 inhibitors?
- How do dosing logistics (infusion cadence and clinic capacity) affect market growth for Ultomiris?
